Michael S Kiernan1, Kartik S Sundareswaran2, Duc Thinh Pham3, Navin K Kapur4, Naveen L Pereira5, Martin Strueber6, David J Farrar2, David DeNofrio4, Joseph G Rogers7. 1. Divisions of Cardiology, Tufts Medical Center, Boston, Massachusetts. Electronic address: mkiernan@tuftsmedicalcenter.org. 2. Thoratec Corporation, Pleasanton, California. 3. Division of Cardiac Surgery, Northwestern University, Chicago, Illinois. 4. Divisions of Cardiology, Tufts Medical Center, Boston, Massachusetts. 5. Division of Cardiology, Mayo Clinic, Rochester, Minnesota. 6. Richard DeVos Heart and Lung Transplant Program, Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, Michigan. 7. Division of Cardiology, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Left ventricular assist devices (LVADs) improve survival, quality of life (QOL), and functional capacity (FC) among patients with end-stage heart failure. Few data are available regarding characteristics associated with QOL and FC response. METHODS AND RESULTS: Patients enrolled in the Heartmate II clinical trials that were alive with ongoing LVAD support at 6 months were included. QOL response criteria included scoring above the lowest quartile on either the Minnesota Living With Heart Failure Questionnaire or the Kansas City Cardiomyopathy Questionnaire. FC responder criteria included improvement in 6-minute walk distance (6MWD) >70 meters from baseline, a 6MWD >220 meters at 6 months, or New York Heart Association functional class I or II. Independent variables associated with QOL nonresponse included history of diabetes (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.20-2.78), lower mean pulmonary arterial pressure (OR 0.97, 95% CI 0.95-0.99), or a Heartmate II right ventricular risk score >2 (OR 1.77, 95% CI 1.00-3.12). Variables associated with FC nonresponse included history of COPD (OR 1.92, 95% CI 1.22-3.03) or diabetes (OR 1.52, 95% CI 1.01-2.27). Compared with responders, QOL and FC nonresponders had reduced long-term survival. CONCLUSIONS: Preoperative comorbidities, including diabetes, COPD, and right heart failure, may limit the QOL and FC response to LVAD therapy and should be considered during the shared decision-making process.
BACKGROUND: Left ventricular assist devices (LVADs) improve survival, quality of life (QOL), and functional capacity (FC) among patients with end-stage heart failure. Few data are available regarding characteristics associated with QOL and FC response. METHODS AND RESULTS:Patients enrolled in the Heartmate II clinical trials that were alive with ongoing LVAD support at 6 months were included. QOL response criteria included scoring above the lowest quartile on either the Minnesota Living With Heart Failure Questionnaire or the Kansas City Cardiomyopathy Questionnaire. FC responder criteria included improvement in 6-minute walk distance (6MWD) >70 meters from baseline, a 6MWD >220 meters at 6 months, or New York Heart Association functional class I or II. Independent variables associated with QOL nonresponse included history of diabetes (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.20-2.78), lower mean pulmonary arterial pressure (OR 0.97, 95% CI 0.95-0.99), or a Heartmate II right ventricular risk score >2 (OR 1.77, 95% CI 1.00-3.12). Variables associated with FC nonresponse included history of COPD (OR 1.92, 95% CI 1.22-3.03) or diabetes (OR 1.52, 95% CI 1.01-2.27). Compared with responders, QOL and FC nonresponders had reduced long-term survival. CONCLUSIONS: Preoperative comorbidities, including diabetes, COPD, and right heart failure, may limit the QOL and FC response to LVAD therapy and should be considered during the shared decision-making process.
Authors: Windy W Alonso; Kenneth M Faulkner; Bunny J Pozehl; Judith E Hupcey; Lisa A Kitko; Christopher S Lee Journal: Res Nurs Health Date: 2020-07-06 Impact factor: 2.228
Authors: Divya Soman; James Hodovan; Conrad J Macon; Brian P Davidson; J Todd Belcik; James O Mudd; Byung S Park; Jonathan R Lindner Journal: J Am Soc Echocardiogr Date: 2021-12-29 Impact factor: 7.722
Authors: Michael S Kiernan; E Wilson Grandin; Marshall Brinkley; Navin K Kapur; Duc Thinh Pham; Robin Ruthazer; J Eduardo Rame; Pavan Atluri; Edo Y Birati; Guilherme H Oliveira; Francis D Pagani; James K Kirklin; David Naftel; Robert L Kormos; Jeffrey J Teuteberg; David DeNofrio Journal: Circ Heart Fail Date: 2017-10 Impact factor: 8.790
Authors: Djordje G Jakovljevic; Magdi H Yacoub; Stephan Schueler; Guy A MacGowan; Lazar Velicki; Petar M Seferovic; Sandeep Hothi; Bing-Hsiean Tzeng; David A Brodie; Emma Birks; Lip-Bun Tan Journal: J Am Coll Cardiol Date: 2017-04-18 Impact factor: 24.094